Research programme: histamine receptor antagonists - Ziarco

Drug Profile

Research programme: histamine receptor antagonists - Ziarco

Latest Information Update: 04 Apr 2017

Price : $50

At a glance

  • Originator Pfizer
  • Developer Ziarco
  • Class Small molecules
  • Mechanism of Action Histamine H3 receptor antagonists; Histamine H4 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Allergic rhinitis; Hypersensitivity

Most Recent Events

  • 01 Dec 2014 Preclinical trials in Allergic rhinitis in United Kingdom (PO)
  • 01 Dec 2014 Preclinical trials in Hypersensitivity in United Kingdom (PO)
  • 05 Nov 2012 Early research in Allergic rhinitis in United Kingdom (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top